The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -20.45 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -4.04 — no flag raisedOK
- Earnings quality 63/100 — worth a closer lookWatch
Leadership changes
From Cardiff Oncology, Inc.'s own filings, the day they're filed.
- Ajay Aggarwal · Chief Operating Officer · appointmenteff. 2026-04-27
- Mani Mohindru · President · appointmenteff. 2026-04-09
- Josh Muntner · Chief Financial Officer · appointmenteff. 2026-04-06
Latest filings
- 8-K · Company announcement2026-06-11
- 8-K · Company announcement2026-06-03
- 8-K · Company announcement2026-05-29
- 8-K · Company announcement2026-05-19
- 8-K · Company announcement2026-05-14
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Cardiff Oncology, Inc., every answer cited🔒
- The Intelligence Brief — added when Cardiff Oncology, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.